Simon Dökel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Simon Dökel has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Achim D. Gruber
Institute of Veterinary Pathology, Freie Universität Berlin, Berlin, Germany
2 shared publications - Andreas C. Hocke
Department of Infectious Diseases, Respiratory Medicine and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
1 shared publication - Angeles Mecate-Zambrano
Institute of Virology (IVM), University of Münster, 48149 Münster, Germany
1 shared publication Barbara Biere
Robert Koch Institute - Unit 17 “Influenza and other Respiratory Viruses
1 shared publicationBenedikt Obermayer
Charité - Universitätsmedizin Berlin
1 shared publication- Christian Drosten
Charité - Universitätsmedizin Berlin - Institute of Virology
1 shared publication
Latest Publications
- Open Access
- 15 March 2026
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 74 (3) , 321-337
The Chloride Channel Regulator, Calcium-Activated-1 Is Expressed in Synoviocytes and Articular Chondrocytes in Health and Disease
The chloride channel regulator, calcium-activated-1, CLCA1, acts as a multifunctional secreted glycoprotein in anion channel modulation, mucus homeostasis, immune regulation, and other functions. So far, it has been described in goblet and other mucus-producing cells in mucous membranes, primarily of the respiratory, alimentary, and urogenital tracts. Here, we identify the expression of CLCA1 in fibroblast-like synoviocytes and superficial as well as, to a lesser extent, intermediate zone chondrocytes of diarthrodial articular joints. The expression pattern was found to be conserved in major joints in mice, pigs, and humans. First analyses of degenerate or infectious inflammatory joint conditions in mice or pigs, respectively, suggest rather continuous expression levels in articular disease. We speculate that CLCA1 may be involved in articular anion conductance, proteoglycan homeostasis, and inflammation of articular joints, possibly similar to analogous functions of this molecule as established in mucous membranes of the lungs and intestine:
- 15 March 2026
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 74 (3) , 321-337
Open AccessThe Chloride Channel Regulator, Calcium-Activated-1 Is Expressed in Synoviocytes and Articular Chondrocytes in Health and Disease
The chloride channel regulator, calcium-activated-1, CLCA1, acts as a multifunctional secreted glycoprotein in anion channel modulation, mucus homeostasis, immune regulation, and other functions. So far, it has been described in goblet and other mucus-producing cells in mucous membranes, primarily of the respiratory, alimentary, and urogenital tracts. Here, we identify the expression of CLCA1 in fibroblast-like synoviocytes and superficial as well as, to a lesser extent, intermediate zone chondrocytes of diarthrodial articular joints. The expression pattern was found to be conserved in major joints in mice, pigs, and humans. First analyses of degenerate or infectious inflammatory joint conditions in mice or pigs, respectively, suggest rather continuous expression levels in articular disease. We speculate that CLCA1 may be involved in articular anion conductance, proteoglycan homeostasis, and inflammation of articular joints, possibly similar to analogous functions of this molecule as established in mucous membranes of the lungs and intestine:
- Open Access
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Human Lungs Show Limited Permissiveness for SARS-CoV-2 Due to Scarce ACE2 Levels But Strong Virus-Induced Immune Activation in Alveolar Macrophages
SARS-CoV-2 utilizes the ACE2 transmembrane peptidase as essential cellular entry receptor. Several studies have suggested abundant ACE2 expression in the human lung, inferring strong permissiveness to SARS-CoV-2 infection with resultant alveolar damage and lung injury. Against this expectation, we provide evidence that ACE2 expression must be considered scarce, thereby limiting SARS-CoV-2 propagation in the human alveolus. Instead, spectral imaging of ex vivo infected human lungs and COVID-19 autopsy samples depicted that alveolar macrophages were frequently positive for SARS-CoV-2, indicating viral phagocytosis. Single-cell transcriptomics of SARS-CoV-2 infected human lung tissue further revealed strong inflammatory and anti-viral activation responses in macrophages and monocytes, comparable to those induced by MERS-CoV, but with virus-specific gene expression profiles. Collectively, our findings indicate that severe lung injury in COVID-19 likely results from an overwhelming immune activation rather than direct viral damage of the alveolar compartment. Funding: ACH, LES, SH were supported by Berlin University Alliance GC2 Global Health (Corona Virus Pre-Exploration Project). ACH, SH, TW and CD were supported by BMBF (RAPID) and ACH, SH by BMBF (alvBarriereCOVID-19). KH, LB, SL, SH, CD, TW, ACH were funded by BMBF (NFN-COVID 19, Organo-Strat). KH, NS, LES, MW, SH, ADG, CD, TW and ACH were supported by DFG (SFB-TR 84). ACH was supported by BIH, Charite 3R, and Charité-Zeiss MultiDim. KH was supported by BMBF (Camo-COVID-19). MW, NS and SH was supported by BMBF (PROVID). MW and NS was supported by BIH and BMBF (SYMPATH, CAPSyS, NAPKON). BO and DB were funded through the BIH Clinical Single Cell Bioinformatics Pipeline. LB was supported by the BMBF (CoIMMUNE), the DFG (KFO 342) and the IZKF of the Medical Faculty of the WWU. Conflict of Interest: The authors declare no competing interests. Ethical Approval: The study was approved by the ethics committee at the Charité clinic (projects EA2/079/13) and Ärztekammer Westfalen-Lippe and of the Westfälischen Wilhelms-Universität (AZ: 2016-265-f-S). Written informed consent was obtained from all patients.
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessHuman Lungs Show Limited Permissiveness for SARS-CoV-2 Due to Scarce ACE2 Levels But Strong Virus-Induced Immune Activation in Alveolar Macrophages
SARS-CoV-2 utilizes the ACE2 transmembrane peptidase as essential cellular entry receptor. Several studies have suggested abundant ACE2 expression in the human lung, inferring strong permissiveness to SARS-CoV-2 infection with resultant alveolar damage and lung injury. Against this expectation, we provide evidence that ACE2 expression must be considered scarce, thereby limiting SARS-CoV-2 propagation in the human alveolus. Instead, spectral imaging of ex vivo infected human lungs and COVID-19 autopsy samples depicted that alveolar macrophages were frequently positive for SARS-CoV-2, indicating viral phagocytosis. Single-cell transcriptomics of SARS-CoV-2 infected human lung tissue further revealed strong inflammatory and anti-viral activation responses in macrophages and monocytes, comparable to those induced by MERS-CoV, but with virus-specific gene expression profiles. Collectively, our findings indicate that severe lung injury in COVID-19 likely results from an overwhelming immune activation rather than direct viral damage of the alveolar compartment. Funding: ACH, LES, SH were supported by Berlin University Alliance GC2 Global Health (Corona Virus Pre-Exploration Project). ACH, SH, TW and CD were supported by BMBF (RAPID) and ACH, SH by BMBF (alvBarriereCOVID-19). KH, LB, SL, SH, CD, TW, ACH were funded by BMBF (NFN-COVID 19, Organo-Strat). KH, NS, LES, MW, SH, ADG, CD, TW and ACH were supported by DFG (SFB-TR 84). ACH was supported by BIH, Charite 3R, and Charité-Zeiss MultiDim. KH was supported by BMBF (Camo-COVID-19). MW, NS and SH was supported by BMBF (PROVID). MW and NS was supported by BIH and BMBF (SYMPATH, CAPSyS, NAPKON). BO and DB were funded through the BIH Clinical Single Cell Bioinformatics Pipeline. LB was supported by the BMBF (CoIMMUNE), the DFG (KFO 342) and the IZKF of the Medical Faculty of the WWU. Conflict of Interest: The authors declare no competing interests. Ethical Approval: The study was approved by the ethics committee at the Charité clinic (projects EA2/079/13) and Ärztekammer Westfalen-Lippe and of the Westfälischen Wilhelms-Universität (AZ: 2016-265-f-S). Written informed consent was obtained from all patients.